Immunic Inc (NASDAQ:IMUX, FRA:10VA) chief operating officer Jason Tardio talked with Proactive’s Stephen Gunnion about the importance of science-led innovation in tackling neurological diseases, particularly multiple sclerosis, on World Health Day 2026.
Tardio highlighted that the biotech industry is fundamentally grounded in scientific research and data, noting that “everything we do is rooted in science.” He explained that Immunic is focused on developing innovative therapies designed to improve patient outcomes and address significant unmet medical needs.
The discussion centred on multiple sclerosis (MS), a complex neurological disease that continues to present challenges despite decades of progress. Tardio pointed out that while advancements have been made, “the disease is not solved for,” with many patients still experiencing disability progression and requiring safer, more tolerable treatments.
He emphasised the urgent need for innovation, particularly in progressive forms of MS where treatment options remain extremely limited. Immunic’s lead asset, vidofludimus calcium, is being developed as a novel approach aimed at addressing the full spectrum of the disease.
Tardio also reinforced the broader mission of the healthcare and biotech sectors, stating that the ultimate goal is to help individuals “live a better quality of life” and “a healthier life longer.”
Watch the full interview to learn more about Immunic’s approach to advancing MS treatment through science.
For more videos like this, visit Proactive’s YouTube channel, like this video, subscribe to the channel, and enable notifications so you never miss an update.
#Immunic #MultipleSclerosis #BiotechInnovation #Healthcare #MSResearch #DrugDevelopment #ClinicalTrials #Neurology #WorldHealthDay #ScienceDriven #VidofludimusCalcium #PharmaNews #BiotechNews